SWOG clinical trial number
CTSU/C90203

A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer

Closed
Phase
Abbreviated Title
High Risk, Clinically Localized PCa, Neo-Adjuvant Docetaxel + AD, Ph III
Status Notes
This study will be permanently closed to new patient accrual effective 4:30 p.m. EST, Friday, October 2, 2015.
Activated
07/01/2007
Closed
10/02/2015
Participants
CTSU

Research committees

Genitourinary Cancer

Treatment

Docetaxel Leuprolide Acetate Goserelin Acetate

Eligibility Criteria Expand/Collapse

The Southwest Oncology Group has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for information and registration procedures.

Publication Information Expand/Collapse

2020

Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer

J Eastham;G Heller;S Halabi;JP Monk;H Beltran;M Gleave;CP Evans;S Clinton;R Szmulewitz;J Coleman;D Hillman;CR Watt;O Hahn;ME Taplin;JK Parsons;E Small;J Mohler;MJ Morris Journal of Clinical Oncology Sep 10;38(26):3042-3050; Jul 24;JCO2000315. doi: 10.1200/JCO.20.00315. Online ahead of print

PMid: PMID32706639 | PMC number: PMC7479762

2019

CALGB 90203 (Alliance): Radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC)

JA Eastham;G Heller;S Halabi;P Monk;SK Clinton;R Zelig Szmulewitz;J Coleman;M Gleave;CP Evans;CW Hillman;H Beltran;ME Taplin;OM Hahn;JK Parsons;EJ Small;J Mohler;MJ Morris J Clin Oncol 37(suppl; abstr 5079; American Society of Clinical Oncology (5/31-6/4/19, Chicago IL), poster session

CALGB 90203 (ALLIANCE): RADICAL PROSTATECTOMY WITH OR WITHOUT NEOADJUVANT CHEMOHORMONAL THERAPY IN MEN WITH CLINICALLY LOCALIZED, HIGH RISK PROSTATE CANCER

JA Eastham;G Heller;S Halabi;JP Monk;H Beltran;M Gleave;CP Evans;S Clinton;R Szmulewitz;J Coleman;D Hillman;C Watt;O Hahn;M Taplin;E Small;J Mohler;MJ Morris American Urological Association Annual Meeting (May 3-6, 2019, Chicago, IL), poster

Other Clinical Trials

SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
10%
Open
Phase
SWOG Clinical Trial Number
CTSU/A031901

Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase